Detalhe da pesquisa
1.
Antiviral and Anti-Inflammatory Therapeutic Effect of RAGE-Ig Protein against Multiple SARS-CoV-2 Variants of Concern Demonstrated in K18-hACE2 Mouse and Syrian Golden Hamster Models.
J Immunol;
212(4): 576-585, 2024 Feb 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38180084
2.
Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects.
J Immunol;
197(12): 4603-4612, 2016 12 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27913647
3.
Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens.
J Virol;
90(8): 4133-4149, 2016 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26865719
4.
Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques.
PLoS Pathog;
11(8): e1005042, 2015 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26237403
5.
Enhanced in vitro transcytosis of simian immunodeficiency virus mediated by vaccine-induced antibody predicts transmitted/founder strain number after rectal challenge.
J Infect Dis;
211(1): 45-52, 2015 Jan 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24850790
6.
The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells.
PLoS Pathog;
9(11): e1003776, 2013.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24278022
7.
Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys.
Nature;
457(7225): 87-91, 2009 Jan 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18997770
8.
Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose.
Retrovirology;
11: 8, 2014 Jan 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24444350
9.
Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques.
J Virol;
87(19): 10447-59, 2013 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23885083
10.
Association of Fcγ receptor IIIa genotype with the rate of HIV infection after gp120 vaccination.
Blood;
120(14): 2836-42, 2012 Oct 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22915639
11.
A Broad-Spectrum Multi-Antigen mRNA/LNP-Based Pan-Coronavirus Vaccine Induced Potent Cross-Protective Immunity Against Infection and Disease Caused by Highly Pathogenic and Heavily Spike-Mutated SARS-CoV-2 Variants of Concern in the Syrian Hamster Model.
bioRxiv;
2024 Feb 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38405942
12.
A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques.
J Virol;
86(11): 6189-96, 2012 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22457527
13.
Fc receptor but not complement binding is important in antibody protection against HIV.
Nature;
449(7158): 101-4, 2007 Sep 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17805298
14.
Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal.
Retrovirology;
9: 57, 2012 Jul 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22805180
15.
Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12.
J Immunol;
185(11): 6876-82, 2010 Dec 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21041724
16.
Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L.
J Virol;
84(3): 1302-13, 2010 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19906907
17.
Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.
PLoS Pathog;
5(5): e1000433, 2009 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19436712
18.
Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys.
J Virol;
83(18): 9584-90, 2009 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19553307
19.
Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.
J Virol;
82(24): 12449-63, 2008 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18842730
20.
Heavily glycosylated, highly fit SIVMne variants continue to diversify and undergo selection after transmission to a new host and they elicit early antibody dependent cellular responses but delayed neutralizing antibody responses.
Virol J;
5: 90, 2008 Aug 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18680596